3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Expanded_access
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Pancreatic Neoplasms
2
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Gemcitabine
677
130-nm albumin-bound paclitaxel
197
Fluorouracil
184
Oxaliplatin
173
Albumin-Bound Paclitaxel
151
Capecitabine
137
Leucovorin
129
Irinotecan
111
Radiotherapy
95
Taxes
83
pembrolizumab
80
Cisplatin
71
Erlotinib Hydrochloride
69
Radiosurgery
67
Nivolumab
56
Bevacizumab
54
Drug Therapy
52
Cyclophosphamide
48
Magnetic Resonance Spectroscopy
45
folfirinox
42
Docetaxel
41
Cetuximab
40
irinotecan sucrosofate
36
Specimen Handling
36
S 1 (combination)
36
Biopsy
30
Radiation
29
Paclitaxel
29
Ipilimumab
27
Surgical Procedures, Operative
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Neoplasms
×
pegilodecakin
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled
NCT02923921
2020-10-19
Sequoia
Eli Lilly and Company
Phase 3
Completed
567 enrolled
17 charts